Dinesh P. de Alwis
Intarcia Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab(2018)305 cited
- → Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance(2018)207 cited
- → Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice(2007)202 cited
- → Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation(2005)175 cited
- → Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer(2016)159 cited
- → A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation(2020)154 cited
- → Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example(2015)152 cited
- → A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy(2004)150 cited
- → Considerations in the design and development of transport inhibitors as adjuncts to drug therapy(2003)127 cited
- → Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic(2017)98 cited